Logo
x

Search

Subscribe Now

Dry Eye

Bausch Health Initiates Second P-III Study for NOV03 (perfluorohexyloctane) to Treat DED Associated With MGD

Bausch Health Initiates Second P-III Study for NOV03 (perfluorohexyloctane) to Treat DED Associated With MGD

  • November 25, 2020
Novaliq Reports the EMA Acceptance of MAA for CyclASol (ciclosporin ophthalmic solution) to Treat Dry Eye Disease

    Novaliq Reports the EMA Acceptance of MAA for CyclASol (ciclosporin ophthalmic solution) to Treat Dry Eye Disease

    • August 24, 2023
    Zhaoke Ophthalmology Signed an Exclusive License, Supply and Distribution Agreement with Eyedetec Medical to Commercialize Eye Lipid Mobilizer

      Zhaoke Ophthalmology Signed an Exclusive License, Supply and Distribution Agreement with Eyedetec Medical to Commercialize Eye Lip...

      • June 9, 2023
      Bausch + Lomb and Novaliq Receives the US FDA’s Approval of Miebo for Signs and Symptoms of Dry Eye Disease

        Bausch + Lomb and Novaliq Receives the US FDA’s Approval of Miebo for Signs and Symptoms of Dry Eye Disease

        • May 18, 2023
        Aldeyra Therapeutics Reports the US FDA Acceptance of NDA for Reproxalap to Treat Dry Eye Disease

          Aldeyra Therapeutics Reports the US FDA Acceptance of NDA for Reproxalap to Treat Dry Eye Disease

          • February 8, 2023
          HanAll

            HanAll's Licensed Partner Entered into an Exclusive Sublicense Agreement with CSPC NBP Pharma for Batoclimab

            • October 11, 2022
            Oculis Published P-II Study Results of Licaminlimab (OCS-02) for the Treatment of Severe Dry Eye Disease in Clinical Ophthalmology

              Oculis Published P-II Study Results of Licaminlimab (OCS-02) for the Treatment of Severe Dry Eye Disease in Clinical Ophthalmology

              • August 24, 2022
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.